COVID-19

AIM ImmunoTech Enrolls and Doses First Subject in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID ConditionsAIM ImmunoTech Enrolls and Doses First Subject in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions

AIM ImmunoTech Enrolls and Doses First Subject in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions

Preliminary Ampligen data demonstrates potential to be an effective treatment option for post-COVID conditions Enrollment expected to be completed in…

2 years ago
iCAD Offers ROI Analysis Based on Real-World Results from its ProFound Breast AI Suite at AHRA Annual MeetingiCAD Offers ROI Analysis Based on Real-World Results from its ProFound Breast AI Suite at AHRA Annual Meeting

iCAD Offers ROI Analysis Based on Real-World Results from its ProFound Breast AI Suite at AHRA Annual Meeting

Company’s ROI Tool offers preview of business value the ProFound Breast AI Suite offers to clinicians and imaging facilitiesNASHUA, N.H.,…

2 years ago
Tonix Pharmaceuticals Announces Initiation of Enrollment in the MGH Phase 2 ‘POWER’ Study of TNX-1900 (Intranasal Potentiated Oxytocin) for the Treatment of Pediatric ObesityTonix Pharmaceuticals Announces Initiation of Enrollment in the MGH Phase 2 ‘POWER’ Study of TNX-1900 (Intranasal Potentiated Oxytocin) for the Treatment of Pediatric Obesity

Tonix Pharmaceuticals Announces Initiation of Enrollment in the MGH Phase 2 ‘POWER’ Study of TNX-1900 (Intranasal Potentiated Oxytocin) for the Treatment of Pediatric Obesity

Preliminary Data Suggest that Oxytocin May Simultaneously Reduce Energy Intake and Increase Energy Expenditure TNX-1900 (Intranasal Potentiated Oxytocin) May Serve…

2 years ago
EyePoint Pharmaceuticals Announces Chief Executive Officer TransitionEyePoint Pharmaceuticals Announces Chief Executive Officer Transition

EyePoint Pharmaceuticals Announces Chief Executive Officer Transition

– Jay S. Duker, M.D., Previously President and Chief Operating Officer, Appointed President and Chief Executive Officer – – Nancy S.…

2 years ago
Tango Therapeutics Announces First Patient Dosed in TNG462 Phase 1/2 Trial in Patients With MTAP-deleted Solid TumorsTango Therapeutics Announces First Patient Dosed in TNG462 Phase 1/2 Trial in Patients With MTAP-deleted Solid Tumors

Tango Therapeutics Announces First Patient Dosed in TNG462 Phase 1/2 Trial in Patients With MTAP-deleted Solid Tumors

BOSTON, July 10, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering the…

2 years ago
CancerVAX CEO Ryan Davies Discusses Biotech Entrepreneurship with Pyxis Oncology CEO Dr. Lara SullivanCancerVAX CEO Ryan Davies Discusses Biotech Entrepreneurship with Pyxis Oncology CEO Dr. Lara Sullivan

CancerVAX CEO Ryan Davies Discusses Biotech Entrepreneurship with Pyxis Oncology CEO Dr. Lara Sullivan

The two industry leaders focus on navigating the biotech industry and immuno-oncology researchLEHI, Utah, July 10, 2023 (GLOBE NEWSWIRE) --…

2 years ago
Nicox Estimates Potential Annual Global Net Sales for NCX 470 of over $300 millionNicox Estimates Potential Annual Global Net Sales for NCX 470 of over $300 million

Nicox Estimates Potential Annual Global Net Sales for NCX 470 of over $300 million

Press ReleaseNicox Estimates Potential Annual Global Net Sales for NCX 470 of over $300 millionNCX 470 therapeutic profile positively received…

2 years ago
Xtant Medical Announces Closing of $15 Million Private PlacementXtant Medical Announces Closing of $15 Million Private Placement

Xtant Medical Announces Closing of $15 Million Private Placement

BELGRADE, Mont., July 07, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company…

2 years ago
Axsome Therapeutics Initiates FOCUS Phase 3 Trial of Solriamfetol for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in AdultsAxsome Therapeutics Initiates FOCUS Phase 3 Trial of Solriamfetol for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults

Axsome Therapeutics Initiates FOCUS Phase 3 Trial of Solriamfetol for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults

NEW YORK, July 07, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel…

2 years ago
Late-Breaking KidneyIntelX Evidence Released at 83rd American Diabetes Association Scientific SessionsLate-Breaking KidneyIntelX Evidence Released at 83rd American Diabetes Association Scientific Sessions

Late-Breaking KidneyIntelX Evidence Released at 83rd American Diabetes Association Scientific Sessions

12 Months KidneyIntelX™ in vitro prognostic testing continued to demonstrate clinical actions that lead to improvement in both diabetes (A1C…

2 years ago